Autoimmune thrombocytopenia related to chronic hepatitis C virus infection

Hematology

Volumn 14, Issue 1, 2009, Pages 49-58

  de Almeida, Adilson José ^a,b   Campos de Magalhaes M ^b   Antonietti, C L ^b   Brandao Mello C E ^b   da Silva, M L P ^a   de Oliveira, R V ^a   do Espirito Santo M P ^a   Yoshida, C F T ^a   Lampe, E ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Autoimmune thrombocytopenia; Chronic hepatitis C; HCV; Platelets

Indexed keywords

ALANINE AMINOTRANSFERASE; DEXAMETHASONE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTIBODY; GLYCOPROTEIN IB; GLYCOPROTEIN IB ANTIBODY; IMMUNOGLOBULIN; PEGINTERFERON ALPHA2B; RHESUS D ANTIBODY; RIBAVIRIN; THROMBIN RECEPTOR; THROMBIN RECEPTOR ANTIBODY; THROMBOCYTE ANTIBODY; THROMBOPOIETIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 2 ANTIBODY; VIRUS RNA; ALPHA2B INTERFERON; ANTIBODY; ANTIVIRUS AGENT; PEGINTERFERON ALFA-2B;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD TRANSFUSION; BONE MARROW EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG ABUSE; ECCHYMOSIS; EPISTAXIS; FEMALE; GENOTYPE; GINGIVA BLEEDING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RISK FACTOR; SURGICAL RISK; THROMBOCYTE COUNT; UTERUS BLEEDING; VIRUS LOAD; AGED; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; VIROLOGY;

ADULT; AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PLATELET COUNT; PLATELET MEMBRANE GLYCOPROTEINS; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 64949110717     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X385106     Document Type: Article

References (57)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
2. Vassilopoulos D, Calabrese LH. Extrahepatic immunological complications of hepatitis C virus infection. AIDS 2005; 19: S123-127.
3. García-Carrasco M, Escárcega RO. Extrahepatic autoimmune manifestations of chronic hepatitis C vírus infection. Ann Hepatol 2006; 5: 161-163.
4. Okuse C, Yotsuyanagi H, Koike K. Hepatitis C as a systemic disease:vIrus and host immunologic responses underlie hepatic and extrahepatic manifestations. J Gastroenterol 2007; 42: 857-865.
5. Sène D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: A review. Metab Brain Dis 2004; 19: 357-381.
6. Zignego AL, Ferri C, Pileri SA, et al. for the Italian Association of the Study of liver Commission on Extrahepatic Manifestations of HCV Infection. Extrahepatic manifestations of hepatitis C virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39: 2-17.
7. Craxì A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: A systemic disease. Mol Aspects Med 2008; 29: 85-95.
8. Weksler BB. Review article: The pathophysyology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007; 26: 13-19.
9. de Almeida AJ, Campos-de-Magalhaães M, de Melo Marçal OP, et al. Hepatitis C virus associated thrombocytopenia: A controlled prospective, virological study. Ann Hematol 2004; 83: 434-440.
10. Sakuraya M, Murakami H, Uchiumi H, et al. Steroid-refractory chronic idiopathic thrombocytopenic purpura associated with hepatitis C virus infection. Eur J Haematol 2002; 68: 49-53.
11. Sanjo A, Satoi J, Ohnishi A, et al. Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. J Gastroenterol Hepatol 2003; 18: 638-644.
12. Nakagima H, Takagi H, Yamazaki Y, et al. Immune thrombocytopenic purpura in patients with hepatitis C virus infection. Hepatogastroenterology 2005; 52: 1197-2000.
13. Sekiguchi T, Nagamine T, Takagi H, et al. Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients with accompanying hepatitis C. World J Gastroenterol 2006; 12: 1205-1210.
14. Chalasani N, Gitlin N. Thrombocytopenia associated with hepatitis C: Is it real? Am J Gastroenterol 1997; 92: 1234-1235.
15. Pockros PJ, Duchini A, McMillan R, et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002; 8: 2040-2045.
16. Kajihara M, Kato S, Okazaki Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37: 1267-1276
17. Panzer S, Seel E, Brunner M, et al. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol 2006; 77: 513-517.
18. Colin C, Lanoir D, Touzet S, et al. HEPATITIS Group. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: An analysis of the literature. J Viral Hepat 2001; 8: 87-95.
19. Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-2634
20. de Almeida AJ, Campos-de-Magalhães M, Brandão-Mello CE, et al. Detection of hepatitis C virus in platelets: Evaluating its relationship to host and viral factors. Hepatogastroenterology 2007; 54: 964-968.
21. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237-238.
22. Chayama K, Suzuki F, Tsubota A, et al. Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype. J Virol Methods 2001; 95: 33-45
23. Lampe E, Yoshida CF, de Oliveira RV, et al. Molecular analysis and patterns of ALT and hepatitis C virus seroconversion in haemodialysis patients with acute hepatitis. Nephrology (Carlton) 2008; 13: 186-192.
24. GenBank® database [Internet]. Bethesda, (MD): National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health. February 2008 (cited March 27, 2008). Available from: http://www.ncbi.nlm.nih.gov/Genbank/index.html; accessed 18 February 2008.
25. Kumar S, Tamura K, Nei M. MEGA3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 2004; 5: 150-63.
26. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
27. Cooper N, Bussel J. The pathogenesis of immune thrombocytopenic púrpura. Br J Haematol 2006; 133: 364-374.
28. Poordad F. Review article: Thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007; 26: 5-11.
29. Streiff MB, Mehta S, Thomas DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002; 35: 947-952.
30. Wang CS, Yao WJ, Wang ST, et al. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: Implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 2004; 39: 790-796.
31. Monteagudo M, Amengual MJ, Muñoz L, et al. Reticulated platelets as a screening test to identify thrombocytopenia aetiology. QJM 2008; 101: 549-555.
32. Aster RH. Pooling of platelets in the spleen: Role in the pathogenesis of 'hypersplenic' thrombocytopenia. J Clin Invest 1966; 45: 645-657.
33. Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113: 590-595.
34. Nagamine T, Ohtuka T, Arai T, et al. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996; 24: 135-140.
35. Silva M, Li X, Cheinquer H, et al. HCV associated idiophatic thrombocytopenic purpura (ITP). Gastroenterology 1992; 102: A889.
36. Hamaia S, Li C, Allain JP. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood 2001; 98: 2293-2300.
37. Bordin G, Ballar ̧M, Zigrossi P, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: A direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995; 13: S39-43.
38. Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: An overview. World J Gastroenterol 2007; 13: 2467-2478.
39. Landau DA, Saadoun D, Calabrese LH, et al. The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 2007; 6: 581-587.
40. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 1994; 19: 841-848.
41. Ramos-Casals M, Garía-Carrasco M, López-Medrano F, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: Clinical description of 35 cases. Medicine (Baltimore) 2003; 82: 87-96.
42. Hernández F, Blanquer A, Linares M, et al. Autoimmune thrombocytopenia associated with hepatitis C virus infection. Acta Haematol 1998; 99: 217-220.
43. Bauduer F, Marty F, Larrouy M, et al. Immunologic thrombocytopenic purpura as presenting symptom of hepatitis C infection. Am J Hematol 1998; 57: 338-340.
44. Magrin S, Craxi A, Fabiano C, et al. Hepatitis C viremia in chronic liver disease: Relationship to interferon-alpha or corticosteroid treatment. Hepatology 1994; 19: 273-279
45. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26: 112S-121S.
46. Modi AA, Liang TJ. Hepatitis C: A clinical review. Oral Dis 2008; 14: 10-14.
47. Sagir A, Wettstein M, Heintges T, Häussinger D. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Dig Dis Sci 2002; 47: 562-563.
48. Sevastianos VA, Deutsch M, Dourakis SP, et al. Pegylated interferon-2b-associated autoinmune thrombocytopenia in a patient with chronic hepatitis C. Am J Gastroenterol 2003; 98: 706-707.
49. Fujii H, Kitada T, Yamada T, et al. Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C. Hepatogastroenterology 2003; 50: 841-842.
50. Dimitroulopoulos D, Dourakis SP, Xinopoulos D, et al. Immune thrombocytopenic purpura in a patient treated with interferon alfacon-1. J Viral Hepat 2004; 11: 477-478.
51. Elefsiniots IS, Pantazis KD, Fotos NV, et al. Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 622-623.
52. García-Suárez J, Burgaleta C, Hernanz N, et al. HCV-associated thrombocytopenia: Clinical characteristics and platelet response after recombinant α2b-interferon therapy. Br J Haematol 2000; 110: 98-103.
53. Uygun A, Kadayifci A, Ercin N, et al. Interferon treatment for thrombocytopenia associated with chronic HCV infection. Int J Clin Pract 2000; 54: 683-684.
54. Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol 2001; 68: 202-209
55. Benci A, Caremani M, Tacconi D. Thrombocytopenia in patients with HCV-positive chronic hepatitis: Efficacy of leucocyte interferon-alpha treatment. Int J Clin Pract 2003; 57: 17-19.
56. Karakan T, Cindoruk M, Degertekin B, et al. Combination therapy with pegylated interferon plus ribavirin in the treatment of hepatitis C virus-related thrombocytopenia. Curr Ther Res 2005; 66: 247-253.
57. Iga D, Tomimatsu M, Endo H, et al. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: Possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol 2005; 75: 417-423.